Overview

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in recectable gallbladder carcinoma patients monitored by ctDNA.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Collaborators:
RenJi Hospital
Ruijin Hospital
Shanghai Zhongshan Hospital
Treatments:
Afatinib
Gemcitabine
Oxaliplatin